---

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

---

Schrödinger

🌎 schrodinger.com

Schrödinger is a leading scientific software and biotechnology company that specializes in developing advanced computational tools for drug discovery and materials science. Founded in 1990 and headquartered in New York, Schrödinger's platform supports biopharmaceutical and industrial research globally, with a commitment to innovation in molecular discovery and design.

---

Schrödinger - Latest News and Updates

• Schrödinger has introduced robust prediction of relative binding energies for protein–protein complex mutations using free energy perturbation calculations, replacing the previous focus on OPLS5 polarizability and metal treatment.
• Schrödinger's 2025-1 release introduces a new Kinase Conservation Analysis Interface and augmented AI/ML capabilities for biologics, alongside a Mixed Solvent Molecular Dynamics Interface and ligand unbinding kinetics workflow.
• Schrödinger has introduced new applications including ACTIVE LEARNING APPLICATIONS for machine learning acceleration, BIOLUMINATE for biologics discovery, and a CLOUD COMPUTING ENVIRONMENT for secure simulations, indicating a strategic expansion in digital and cloud-based solutions.
• Schrödinger will participate in the 17th Winter Conference on Medicinal & Bioorganic Chemistry from February 2nd to 6th, 2025, in Steamboat Springs, Colorado, instead of the 29th Biennial ORCS Meeting.
• Schrödinger's recent paper, announced by Principal Scientist Ara M. Abramyan, demonstrates that FEP+ accurately predicts RNA/DNA-targeting ligand affinities using the OPLS4 force field.

• Schrödinger will present their innovations in computational screening for catalyst design at the Organic Reactions Catalysis Society meeting on February 9-13, with a talk by Dr. Pavel Dub on February 12.
• On January 28, 2025, Schrödinger adopted the Sapio Platform to improve data management and lab efficiency, enhancing its in silico drug discovery process.
• The Amity Institute of Biotechnology used the Schrödinger platform for their research on phytomolecules-antibiotics combinations against E. coli.
• Dr. Cheol Soon Lee used Schrödinger's platform to discover a promising compound targeting the previously considered 'undruggable' FoxM1 protein for cancer treatment.

---

Sign up to receive regular updates

If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.